<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; XNPT</title>
	<atom:link href="http://www.stockbloghub.com/tag/xnpt/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(GSK) Company News for April 08, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/04/08/gsk-company-news-for-april-08-2011-corporate-summary/71030</link>
		<comments>http://www.stockbloghub.com/2011/04/08/gsk-company-news-for-april-08-2011-corporate-summary/71030#comments</comments>
		<pubDate>Fri, 08 Apr 2011 17:21:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BBBY]]></category>
		<category><![CDATA[Bed Bath & Beyond Inc.]]></category>
		<category><![CDATA[Coinstar Inc.]]></category>
		<category><![CDATA[Constellation Brands Inc.]]></category>
		<category><![CDATA[CRM]]></category>
		<category><![CDATA[CSTR]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMGN]]></category>
		<category><![CDATA[Immunogen Inc]]></category>
		<category><![CDATA[Lam Research Corporation]]></category>
		<category><![CDATA[LRCX]]></category>
		<category><![CDATA[Pier 1 Imports Inc.]]></category>
		<category><![CDATA[PIR]]></category>
		<category><![CDATA[Salesforce.com]]></category>
		<category><![CDATA[STZ]]></category>
		<category><![CDATA[Xenoport Inc]]></category>
		<category><![CDATA[XNPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71030</guid>
		<description><![CDATA[• Bed Bath &#38; Beyond Inc.’s (NASDAQ:BBBY) shares rose 10.5% a day after the retailer projected earnings ahead of Wall Street’s expectations for the fiscal year ending in Feb. 2012 • Drug developer Immunogen Inc. (NASDAQ:IMGN) reported positive results from a mid-stage study of its breast-cancer treatment • Home-furnishing retailer Pier 1 Imports Inc (NYSE:PIR) reported better-than-expected profit and sales for the fourth quarter and announced plans to buy back up to $100 million in stock • Late Wednesday, XenoPort Inc. (NASDAQ:XNPT) and GlaxoSmithKline PLC (GSK) announced that they had received regulatory approval for a drug to treat restless-legs syndrome • Citigroup analysts added semiconductor equipment maker, Lam Research Corp (NASDAQ:LRCX) to the brokerage’s conviction sell list • Wine and spirits maker Constellation Brands (NYSE:STZ) forecasts its full-year profit above the Street&#8217;s view and announced a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/08/gsk-company-news-for-april-08-2011-corporate-summary/71030/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) GlaxoSmithKline Sees Pipeline Setback</title>
		<link>http://www.stockbloghub.com/2010/02/24/gsk-glaxosmithkline-sees-pipeline-setback/28461</link>
		<comments>http://www.stockbloghub.com/2010/02/24/gsk-glaxosmithkline-sees-pipeline-setback/28461#comments</comments>
		<pubDate>Wed, 24 Feb 2010 18:18:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Xenoport Inc]]></category>
		<category><![CDATA[XNPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28461</guid>
		<description><![CDATA[GlaxoSmithKline (GSK) recently received a pipeline setback when the US Food and Drug Administration (FDA) issued a Complete Response letter (CRL) regarding the company’s New Drug Application (NDA) for Horizant (gabapentin enacarbil) for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS). The FDA did not grant approval based on concerns regarding a preclinical finding of pancreatic acinar cell tumors in rats. Horizant, which has been developed by XenoPort, Inc. (XNPT), is a Transported Prodrug of Pfizer’s (PFE) gabapentin. This is not the first time that Horizant’s approval has been delayed. Earlier, in November 2009, the FDA had pushed back the approval date for Horizant by 90 days stating that a risk evaluation and mitigation strategy (REMS) would be needed for approval. Glaxo and XenoPort are currently evaluating the CRL ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/24/gsk-glaxosmithkline-sees-pipeline-setback/28461/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(XNPT) Xenoport Submits New FDA Drug Application for Restless Leg Syndrome</title>
		<link>http://www.stockbloghub.com/2010/02/08/xnpt-xenoport-submits-new-fda-drug-application-for-restless-leg-syndrome/27297</link>
		<comments>http://www.stockbloghub.com/2010/02/08/xnpt-xenoport-submits-new-fda-drug-application-for-restless-leg-syndrome/27297#comments</comments>
		<pubDate>Mon, 08 Feb 2010 17:55:02 +0000</pubDate>
		<dc:creator>Wax</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Xenoport Inc]]></category>
		<category><![CDATA[XNPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27297</guid>
		<description><![CDATA[We noticed an article last week about Xenoport, Inc. (Nasdaq: XNPT) , a company in the Biotechnology Industry. As is typical for us, we simply are not interested in biotechnology companies since they almost never have earnings, and are normally majority owned by large pharmaceutical firms. The article we read said that Xenoport had submitted an application to the FDA for approval of a new drug that helps with restless leg syndrome. As we learned it was GSK (GlaxoSmithKline), one of Xenoport&#8217;s collaborators, that submitted the new drug application. What pushed us to look into the company was that we know folks that have restless leg syndrome, and they treat it by putting a bar of Palmolive soap near their feet at bedtime. Problem solved. So assuming the worst that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/08/xnpt-xenoport-submits-new-fda-drug-application-for-restless-leg-syndrome/27297/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

